BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient in a Phase 3, Study 106, clinical trial with its lead...
$90 million award expected from the National Institute of Aging and the National Heart, Lung, & Blood Institute to fund largest pragmatic trial with placebo-controlled drug assignment to date In the first statin trial with a non-cardiovascular primary outcome,...
Sofinnova Partners – Life sciences-focused venture capital firm based in Paris, closed its latest fund, Sofinnova Capital IX, oversubscribed at €333 million. The firm now has more than €2B under management with more than €1B raised in the last four years across its...
Third first-in-human cancer treatment trial to open at U of M in last two months MINNEAPOLIS, MN- October 21, 2019 – A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research...
Mark Terry of BioSpace writes: Pfizer announced results from its Phase III clinical trial, JADE MONO-1, of abrocitinib in moderate to severe atopic dermatitis. The drug met all the co-primary and key secondary endpoints related to skin clearance and itch relief...
Key Points Question At birth, are the risks of sensitization to cow’s milk formula and food allergy decreased by avoiding or by supplementing with cow’s milk formula? Findings In this randomized clinical trial involving 312 newborns, risks of sensitization to cow’s...
Email
Text